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Abstract
Human body is colonized by a huge amount of microorganisms mostly located in
the gastrointestinal tract. These dynamic communities, the environment and their
metabolites constitute the microbiota. Growing data suggests a causal role of a
dysbiotic microbiota in several pathologies, such as metabolic and neurological
disorders, immunity dysregulations and cancer, especially the well-studied
colorectal cancer development. However, many were preclinical studies and a
complete knowledge of the pathogenetic mechanisms in humans is still absent.
The gut microbiota can exert direct or indirect effects in different phases of
colorectal cancer genesis. For example, Fusobacterium nucleatum promotes cancer
through cellular proliferation and some strains of Escherichia coli and Bacteroides
fragilis produce genotoxins. However, dysbiosis may also cause a pro-
inflammatory state and the stimulation of a Th17 response with IL-17 and IL-22
secretion that have a pro-oncogenic activity, as demonstrated for Fusobacterium
nucleatum. Microbiota has a crucial role in several stages of postoperative course;
dysbiosis in fact seems related with surgical site infections and Enterococcus
faecalis (and other collagenase-producers microbes) are suggested as a cause of
anastomotic leak. Consequently, unbalanced presence of some species, together
with altered immune response may also have a prognostic role. Microbiota has
also a substantial role in effectiveness of chemotherapy, chemoresistance and in
the related side effects. In other words, a complete knowledge of the fine
pathological mechanisms of gut microbiota may provide a wide range of new
diagnostic tools other than therapeutic targets in the light of tailored medicine.
Key words: Intestinal microbiota; Colorectal cancer; Chemo-resistance; Therapeutic
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Core tip: Microbiome and immunity sciences are fields in rapid evolution gaining
growing attention. The gut microbiota-immunity interplay seems to have a very
important role in all the different phases of colorectal cancer process from oncogenesis
to treatment and prognosis. However, many aspects have been studied only in
experimental models and many theories must still be proved in humans. Providing the
actual state of art of this interplay on the different steps involved in colorectal cancer,
new multidisciplinary studies in humans according to this perspective may be drafted
with the purpose of widening the possibilities of treatment against this frequently
diagnosed pathology.
Citation: Bartolini I, Risaliti M, Ringressi MN, Melli F, Nannini G, Amedei A, Muiesan P,
Taddei A. Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal





A large and diversified group of microorganisms comprehending bacteria, viruses
and fungi  normally  populates  intestinal  mucosa,  such  as  every  other  epithelial
surfaces.  These microbes,  together  with their  metabolic  products  and their  local
microenvironment compose the so-called microbiota[1,2]. Although most of microbiota
strains are not cultivable, recent technologies of genomic sequencing, proteomics and
metagenomic analysis of DNA and RNA allowed the initial  identification of this
population of microorganisms, along with their metabolic production and signal
pathways[1-4].
Nevertheless, these commensal microbes are normally symbiotic and the immune
system has established various tolerance mechanisms[2]; but, in specific conditions, the
equilibrium  break  of  microbiota-immunity  axis  can  be  responsible  for  several
pathologies[2]. The hypothesis that a microorganism could be the cause of a surgical
disease started with the discovery of the Helicobacter pylori role in the genesis of peptic
ulcer. However, since the prevalence of this infection is much more higher than the
incidence of peptic ulcer and since peptic ulcer may present without this infection,
Helicobacter pylori was considered a “not necessary” nor “sufficient” agent to cause
this pathology[1].
Similarly, the potential pathogenetic role of gut microbiota (GM) alteration in the
initiation and progression of colorectal cancer (CRC) has been recently discussed[5].
For this purpose, the microorganisms may have a direct causal role or act perturbing
the local immune response[2]. However, this complex relation is still far from being
completely understood: The microbiota is dynamic, varying on hourly basis and the
“current” microbiota of every person is the result of the individual past exposure to
external agents, making the task to draft general conclusions even more challenging[3].
Several prognostic factors for CRC, for both short-term postoperative outcomes and
long-term oncological  outcomes,  have undoubtedly been recognized[6],  but,  new
potential prognostic factors have been proposed along the years and, in particular, the
potential prognostic role of the microbiota is attracting much attention[3]. However,
differences in microbiota may be at least a part of the cause of different outcomes
achieved in a group of patients treated with the same protocols[3].
Although surgical resection is the cornerstone in the CRC management, whenever
technically feasible, chemotherapy has a complementary role in advanced stages of
disease. Relationship between chemo-resistance and intestinal microbiota has been
advocated[5] but the fine mechanisms still remain unknown. Since chemo-resistance
reduces the survival expectancy, the understanding of the causes of this phenomenon
would be extremely important[5].
The aim of this review is a summary of the actual state of art on a developing
research  field:  The  interplay  between  microbiota  and  inflammatory/immune
response applied on patients undergoing surgery for colorectal cancer, which is a
pathology with high incidence and not negligible morbidity and mortality rates.
Microbiota-based approach may provide a wide and quite revolutionary range of
possibilities to interfere with the different phases of CRC management. Particular
attention was set  on postoperative  outcomes in  order  to  provide inspiration for
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further studies and for new potential strategies for the treatment, but also for the
prevention of colorectal cancer.
GUT MICROBIOTA-IMMUNITY AXIS IN HEALTH
Advent of new technologies in metagenomic field and mass spectrometry pushed the
investigators to analyze the possibility of the existence of both “health-promoting”
and “disease-promoting” ecosystem of microorganisms[1]. Comprising almost 99% of
the total amount of human-associated microbial mass, thousands of different species
of commensal bacteria are required for a healthy gastrointestinal tract[2,7,8].  These
microorganisms are members of different domains comprehending Bacteria, Archaea
and  Eukarya  while  the  four  most  represented  phyla  of  bacteria  are  Firmicutes,
Bacteroidetes, Actinobacteria and Proteobacteria[2]. In particular, about 90% of gut
bacteria belongs to Bacteroidetes and Firmicutes[8,9]. The gut microbiota help in several
host tasks such as in digestion of complex foods (e.g., pectins), vitamins production
and metabolism of glycans and fats[9]. Nevertheless, they have a role in protection
against external pathogens or toxic compounds[2,7,8].
A strong relationship between intestinal microbiota and immunity system has been
described[1,2,5,10].  The innate immune system associated with the mucosal surfaces
accounts for approximately 80% of the active immune system and the great majority
of them are located in the gastrointestinal tract[2].
In addition, the microbiota largely contributes to the development of the lymphoid
tissue[11]  and it  can  modulate  host  immune system,  both  innate  and adaptive[12].
Intestinal microbiota interacts with the immune response elements of the whole body
through dendritic cells or through the stimulation of epithelial receptors, even in
absence of bacterial translocation[1]. Consequently, intestinal microbes may also have
either a negative or a positive effect on the immunity[11]. The Figure 1 represents a
simplified summary of these interactions.
INTESTINAL MICROBIOTA AND IMMUNITY
DYSREGULATION IN COLORECTAL CANCER
The colorectal cancer is the third most frequent cancer worldwide[13] and there is a
probability 4%-5% of a having a CRC in the life span[9]. Various risk factors for CRC
have already been described such as life and dietary style or some comorbidities (e.g.,
ulcerous colitis  or  other conditions)  leading to a persistent  and prolonged colon
inflammation[14,15]. Some bacteria with pro-inflammatory activities may modify the
permeability of the intestinal mucosa easing the translocation of pathogens and their
toxins[2,16]. Furthermore, protracted inflammation causes prolonged oxidative stress
that may be responsible for DNA damages[17], as demonstrated for Escherichia coli in
animal models[18].
Several papers have already highlighted a potential role of intestinal dysbiosis in
the  initiation and progression of  human CRC[14]  taking advantage of  previously
published studies on animal models[19,20]. Dysbiosis is defined as (1) The abnormal and
predominant  presence  of  pathogens  in  an environment  or  (2)  Alterations  of  the
considered normal proportion of the different specimens composing the microbiota[1].
This  new “ecosystem” is  also called pathobiome[21].  Moreover,  the modifications
within  the  microbiota  related with  a  particular  disease  may take  place  at  every
taxonomic  level,  from  the  phylum  to  species  making  the  discovery  of  these
modifications and of their causal effect, an extremely challenging task[4].
Three different pathogenetic models have been proposed. According to the “alfa-
bugs” model, some species (e.g., enterotoxigenic Bacteroides fragilis-ETBF) may have
direct  pro-oncogenic  effect  acting  against  both  immune  system  and  protective
microbial  species[22].  The “bacterial  driver-passenger” model  suggests  that  some
“driver bacteria” promote cancer development through DNA damage. Subsequently,
as consequence of new selective pressures, “passenger bacteria” replace them having
protective  or  cancer-promoting  activities.  The  results  of  this  new  balance  will
determine tumor progression or tissue healing[23].  To note that,  according to this
model,  microbes  responsible  for  tumor  initiation  may  be  absent  during  the
subsequent phases[24]. In the “keystone pathogen” model, some poorly represented
pathogens have the unbalanced ability to alter the equilibrium within the normal
microbiota causing a dysbiosis[25]. These theories are depicted in Figure 2.
Alterations in microbiota composition have been found in samples from normal
colorectal  mucosa,  feces  and tumor  specimen in  patients  affected  by  CRC[5,26-28].
Interestingly, in a case-control study of Flemer, significative differences in microbiota
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Figure 1
Figure 1  Simplified graphic depicting the interactions between the healthy or dysbiotic microbiota and immune system. Dysbiosis is defined as the abnormal
and predominant presence of pathogens in an environment or as alterations of the considered normal proportion of the different specimens composing the
microbiota[1]. The microbiota largely contributes to the development of the lymphoid tissue[11] and it can modulate host immune system (innate and adaptive)[12].
Intestinal microbiota interacts with the immune response elements through dendritic cells. In dysbiosis, a Th17-type of immune response may be activated with
consequent production of IL-17 and IL-22, both having a pro-inflammatory and pro-tumoral effect[2]. Furthermore, IL-22 can favor the expression of inducible nitric
oxide synthase and the subsequently production of oxygen reactive species that are linked to cancer promotion[45].
composition were found between healthy volunteers and people affected by intestinal
polyps[28], suggesting GM alteration in a very early stage of disease. In CRC patients,
higher presence of some microorganisms (e.g.,  Fusobacterium,  Enterococcus faecalis,
Staphylococcaceae or Coriobacteridae) has been reported in previously published
papers together with a lower presence of other microbes including Enterobacteria,
Bifidobacterium, Lactobacillus  and Treponema[29,30].  Coherently with the well-known
different behavior of the right or left colon cancer, different GM modifications have
been found in proximal and distal CRC[28].  Microbiota composition found in right
colonic cancer was more similar to that found in control group with lower activation
of Th17 response[28]. However, further clinical implications are still missing[28].
In particular, an association between Fusobacterium nucleatum (F. nucleatum) and
CRC  has  been  proposed  and  a  suggested  pathogenic  mechanism  involves  the
activation of β-catenin signal pathway causing cellular proliferation (as consequence
of the bindings between FadA and E-cadherin, located on the cells of the intestinal
epithelium)[31].  The F. nucleatum  resulted much more represented in CRC patients
when compared with healthy people[5,17]. Furthermore, its presence seems related with
high-level of instability of microsatellites (MSI)[32,33] and with a CpG island methylator
phenotype[34]. Nevertheless, the number of F. nucleatum and of Bacteroides fragilis (B.
fragilis)  (both in stool sample and tumor tissue) seems to increase along with the
progression from adenoma to adenocarcinoma[35-37].
Similarly, a relation between the population number of B. fragilis and Escherichia coli
(E.  Coli)  (adherent-invasive  ones)  and tumor  size  has  been reported[38].  Possible
pathogenetic  mechanisms  include  bacterial  production  of  toxins,  known  as
genotoxins, able to generate damage to DNA[39]. Examples of these toxins are B. fragilis
toxin,  the cytolethal distending toxin or colibactin toxin produced by polyketide
synthase (pks) positive E. coli or the cytotoxic necrotizing factor 1[24,39]. Higher genes’
expression of B. fragilis toxin and colibactin toxin has been found in patients affected
by familial adenomatous polyposis (FAP) when compared with healthy people[40].
Furthermore,  some microbial  metabolites derived from alimentary intake may
result  genotoxic  and  cytotoxic[41].  Clostrudium,  Bacteroides  and  E.  coli  have  been
reported to have this capacity[23]. In addition to direct promoting effects, intestinal
microbiota  may interfere  in  cancer  proliferation  through the  interplay  with  the
immune  response.  F.  nucleatum  resulted  associated  with  lower  level  of  CD3+  T
cells[32,33],  increased production of TNF-α, IL-6,  IL-12 and IL-17 (all  having a pro-
tumoral effect), upregulation of myeloid-derived cells, and indirect suppression of
CD4+ T cells activity[9,17,31]. Nonetheless, Fap2 protein produced by this microorganism
is able to prevent the antitumor effect of NK cells and other T cells binding with
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Figure 2
Figure 2  Diagram showing the three pathogenetic models involved in colorectal cancer initiation and promotion. Currently, to explain the colorectal cancer
development, three different pathogenetic models have been suggested. According to the “alfa-bugs” model, some species (e.g., Bacteroides fragilis) may have direct
pro-oncogenic effect acting against both immune system and protective microbial species[22]. The “bacterial driver-passenger” model suggests that some “driver
bacteria” promote cancer development through DNA damage. Subsequently, the “passenger bacteria” replace them having protective or cancer-promoting activities.
The results of this new balance will determine tumor progression or tissue healing[23]. Finally, in the “keystone pathogen” model, some poorly represented pathogens
have the unbalanced ability to alter the equilibrium within the normal microbiota causing a dysbiosis[25].
inhibitory receptors[32,42].
In  animal  models,  B.  fragilis  toxin  can  activate  the  signal  transducer  and
transcription-3 (STAT3) pathway that is related with a specific Th17 differentiation.
On the contrary,  inhibition of  IL-17 and IL-23 with antibodies  has  an antitumor
action[39].  Furthermore, in presence of ETBF, regulatory T cells, which are usually
related with an antitumor effect, seem to promote cancer progression through Th17
expansion[43]. Nonetheless, B. fragilis can promote inflammatory response inducing the
signaling NF-κB pathway[44].
Some species of Clostridium (segmented filamentous bacteria) are other microbes
able to activate Th17 producing IL-17 and IL-22 with a pro-inflammatory and pro-
tumor effect[2]. Furthermore, IL-22 can favor the expression of inducible nitric oxide
synthase (iNOS) and subsequently, the production of oxygen reactive species that are
linked to cancer promotion[45]. High levels of IL-23 have also been found in human
CRC and they seem able to activate Th17 response with further production of IL-17 e
IL-22[46]. Other promoting cancer cytokines are IL-6 and 1[17]. Further specific details
will not be object of this review and can be found elsewhere[17].
Despite the crucial role of inflammation in CRC development, use of non-steroidal
anti-inflammatory drugs is not routinely indicated due to their potentially severe side
effects[9].  The  Figure  3  shows some examples  of  suggested  mechanisms.  On the
contrary, some microorganisms seem to have a direct protective effect against tumor
growth,  for  example,  those  producing  short-chain  fatty  acid  (e.g.,  butyrate  or
acetate)[5]. Accordingly with previously published data, Bifidobacterium seems able to
inhibit  tumor  progression  reducing  the  infection  rate  from  enteropathic
microorganism and decreasing the production of bile products[47,48]. Moreover, some
microbes may exhibit an anticancer activity through the interaction with immune
system.  This  positive  effect  is  related  with  the  phagocyte  stimulation,  the
enhancement of NK cytotoxicity and an incremented production of immunoglobulins,
including IgA (that contributes to the mucosal barrier activity)[10,11]. Evidences from
experimental  studies suggest  that  Bifidobacterium  may also favors and antitumor
immune response, inhibiting NF-κB signaling pathway[17,49]. Similarly, Faecalibacterium
prausnitzii may have a positive effect through the induction of IL-10 secretion and the
modulation of Treg response[24]. IL-10 is able to control the proliferation of Th17 cells
stopping cancer progression[2,50]. Furthermore, IL-10 downregulates TNF-α production
and iNOS expression[17].
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Figure 3
Figure 3  Simplified picture illustrating some examples of how microorganisms promote the cancer.Bacteroides fragilis can cause the induction of Th17-type
immune response with upregulation of signal transducer and transcription-3. Moreover, some subtypes of Bacteroides fragilis can secrete the toxin EBTF that can
cause cancer in different ways: (1) Through direct DNA damage; (2) By Treg cells, which in presence of EBTF, seem to promote cancer progression through Th17
expansion[43]; and (3) Through the stimulation of the cleavage of E-cadherin which causes cellular proliferation and intestinal barrier breakage[23]. Nonetheless, B.
fragilis can promote an inflammatory response inducing the signaling NF-κB pathway[44]. The particular group of polyketide synthase (pks) positive Escherichia coli (E.
coli pks+) maintained a genomic island called “pks”. These bacteria can produce the genotoxin “colibactin”, that is able to induce direct DNA damage and,
consequently, to increase the frequency of gene mutations[24,39]. Fusobacterium nucleatum can activate the β-catenin signal pathway causing cellular proliferation as
consequence of the bindings between the bacterial adhesin FadA and E-cadherin which is located on the cells of the intestinal epithelium[31]. Furthermore, it is related
to an increased production of some pro-cancer cytokines, such as TNF-α, IL-6, IL-12 and IL-17. STAT3: Signal transducer and transcription-3; ETBF: Enterotoxigenic
Bacteroides fragilis; E. coli: Escherichia coli; F. nucleatum: Fusobacterium nucleatum.
SURGICAL TREATMENT OF CRC: GUT MICROBIOTA-
IMMUNITY AXIS IN SHORT AND LONG-TERM OUTCOMES
Surgical stress determined by treatments before and after surgery (including bowel
preparation, antibiotic exposure, proton-pump inhibitors’ administration and fasting)
and the operation for CRC itself seem to reduce the GM biodiversity. Consequently,
the balance within the intestinal microbiota and its environment results altered[51].
Deng et al[5] reported a reduction of Bacteroidetes and Firmicutes and an increase of
Proteobacteria in patients surgically treated for CRC when compared to healthy
volunteers. However, although this study is focused in evaluating the microbiota in
fecal samples from 4 different groups (healthy controls, CRC patients, CRC patients
operated and CRC patients treated with chemotherapy), the sample size is very small
(5 patients operated within a total of 69 people involved). However, similar studies on
patients after surgery for CRC confirmed a reduction of obligate anaerobes including
several species of Clostridium, Bacteroides and Prevotella together with a reduction of
Bifidobacterium. On the contrary, Enterococcus, Staphylococcus and Pseudomonas resulted
enriched after surgical treatment[52].
Sze et al[53] evaluated GM changes before and after surgery in patients treated for
adenomas,  advanced adenomas or  carcinomas.  Carcinoma group had the  major
significant variation in microbial composition before and after surgical treatment and,
interestingly,  microbiota  after  surgery  resulted  quite  similar  to  healthy  people.
Consequently, microbial alteration found during the follow-up may be considered as
a potential biomarker for tumor recurrence and may be used to stratify the recurrence
risk[53]. However, the real impact of these findings remains unknown and definitive
conclusions cannot be drawn. The Table 1 summarizes the GM changes in healthy
people and in patients with CRC or surgically treated.
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Table 1  Composition of gut microbiota in healthy people, in patients with colorectal cancer and after colorectal cancer surgery
Healthy Colorectal cancer Post-operation
Bacteroidetes[5] ↑ Staphylococcaceae[28-30] ↑ Proteobacteria[5], ↑ Pseudomonas aeruginosa
Firmicutes[5], ↑ Lachnospiraceae ↑ Clostridium ↑ Coriobacteridae[28-30], ↑ Fusobacterium
nucleatum
[5,32,33]
↓ Bacteroidetes[52], ↓ Bacteroides ovatus, ↓ Prevotella
↑ Bifidobacterium[52], ↓ Fusobacterium nucleatum[5,17] ↑ Enterococcus faecalis[28-30], ↑ Bacteroides fragilis[35-38]
↑ Escherichia coli pks+[38]
↓ Firmicutes[52], ↓ Clostridium but, ↑ Enterococcus, ↑
Staphylococcus




↑: Higher abundance; ↓: Lower abundance; pks+: Polyketide synthase positive.
Short-term outcomes
The well-known better outcomes following bloodless interventions or postoperative
course  not  requiring  an  antibiotic  therapy  may  also  be  related  with  a  better
preservation of the pre-existing microbiota equilibrium[1].  Nevertheless, the good
results obtained following the application of the enhanced recovery after surgery
programs may also be related to a virtuous interaction with the microbiota, as well[1].
Obviously, the ability of the single individual’s microbiota to “refaunate” is of pivotal
importance and many “molecular-level” aspects remain unevaluated. Consequently,
further  investigations  according  with  these  new  perspectives  are  needed.
Nonetheless, the analysis of the different outcomes within a group treated according
to a specific protocol may become more interesting than the comparison between
application or not of the protocol itselfs[1,3].
Postoperative infections
In general surgery and especially in colorectal surgery, the infection rate is still high
(about 15%), being a common readmission cause with an increase in the costs, as
well[3]. Obviously, intraoperative direct contamination is an unquestionable risk factor
for  infections.  However,  after  elective  surgery,  during  which  the  level  of
contamination is low, surgical site infections (SSIs) do exist and Staphylococcus aureus
strains (which belong to cutaneous resident flora) represent the most frequently found
species[3]. Furthermore, cultures from surgical site at the surgery-end are often poor
efficient in predicting a future SSIs and, eventually, the related causal pathogens. This
may have several explanations: (1) The actual instruments are not able to detect the
whole composition or (2) Other still unknown mechanisms may also have a causal
role[3]. According to the proposed “Trojan Horse hypothesis”, some low-abundant
pathogens including methicillin-resistant Staphylococcus aureus or E. faecalis are carried
on by macrophages or  neutrophils  from the gut  to  distant  sites  such as  surgical
wound[3,54].
Nonetheless, in patients considered at high risk for SSIs, these pathogens may have
a  particular  high  virulence  that  resulted  no  more  balanced  by  the  other
microorganisms  after  surgical  insult[3,54].  Prolonged  postoperative  fasting,  not
adequately  compensated  with  enteral  nutrition,  may  alter  the  GM composition
causing a higher surgical site infection rate[55]. Opioid drugs seem to both directly
inhibit immune system and cause microbiota changes, favoring a greater virulence of
the microbes[1,56,57]. On the contrary, the use of competitive opioids antagonists seems
related to a reduction of morbidity rates after colorectal surgery[58].  Consequently,
reducing  preoperative  fasting  and  decreasing  the  use  of  opioids  should  be
encouraged.
Finally, the intestinal microbiota may also have a role in wound healing[57,59].  A
possible mechanism is related to the fermentation of lactic acid from specific species
of the intestinal microbiota that enables the production of the neuropeptide oxytocin
through a stimulation of the vagus nerve. This peptide allows the recruitment of T
cells for an enhanced healing of surgical incision[59].
Anastomotic leak
Anastomotic leak (AL) is the most feared surgery-related complication. It is defined as
a spillage of intestinal material outside the sutured bowel at the anastomotic site,
caused by a defect of intestinal wall. Depending on its severity, it may be related to
further  complications  (including  death)  and  its  management  may  range  from
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observation to surgical treatments[60]. Anastomotic leak rates are reported to range
between 1% and 19%[60]. The well-known risk factors for intestinal AL are: Tension
between the intestinal edges, reduced blood supply to the viscera and technical errors.
However, surgery causes inflammation and inflammatory response may induce gut
dysbiosis. Consequently, a causal role of intestinal pathogens has been reported. In
1954, Cohn conducted a study on dogs demonstrating that colon decontamination
totally avoided anastomotic leak and resulted able to reverse colonic ischemia[61]. More
recently, the causal role of some microorganisms including Enterococcus faecalis and
Pseudomonas aeruginosa, has been suggested[1,62]. In animal models, these species can
cause  the  leak  of  the  anastomosis  producing  high  level  of  collagenase  (matrix
metalloproteinase-MMP), mostly MMP-2 and MMP-9[62]. Abundance of these species
has been found in humans who had surgery complicated by anastomotic leak[1,62] and
copious  presence  of  E.  faecalis  seems  to  persist  into  the  colon  despite  bowel
preparation[52]. Moreover, in animal models, morphine administration has been shown
to  increase  the  presence  of  more  adhesive  E.  faecalis  within  anastomotic  tissue.
Consequently, there is greater collagenase production favoring higher anastomotic
leak rates[63].
Anyhow, collagenase-producing bacteria seem to be necessary but insufficient in
causing an anastomotic leak[3]. The other conditions needed to cause an anastomotic
leak are: (1) The microbiota unbalancing (with protective microbes reduced enough to
unleash  pathogens);  (2)  Inflammatory  response  from anastomotic  tissue  is  also
required to make the pathogens sense and respond to a such modified environment,
and (3) Pathogens must be virulent enough to overcome host defenses[3]. Low rectal
resections and neoadjuvant radiotherapy are independently associated with a higher
anastomotic leak rate. In patients undergoing neoadjuvant radiotherapy, interplay
between radiation and GM alteration has also been advocated as a cause for higher
AL rate. Radiotherapy seems to promote higher levels of virulent anaerobes in the
treated site[21].  On the contrary,  there are commensal  GM bacteria,  which have a
pivotal role in defending epithelial cells of the intestine from apoptosis induced by
radiations[64].
Even in this condition, microbiota seems to have both a protective and harmful
role. Further studies in humans should be performed in order to assess which are
health-promoting  or  noxious  species.  Again,  the  global  result  of  complex
modifications within this environment is more important than the single pathogen
itself confirming the Koch’s postulates[1,65]. The simple analysis of the mere presence of
a  pathogen  in  a  stool  sample  may  seem  quite  reductive  to  achieve  a  complete
understanding of a multifactorial event[3].
Although some recent and apparently countercurrent studies suggesting that oral
antibiosis  and  complete  mechanic  bowel  preparation  allow  the  reduction  of
postoperative morbidity[66], a definitive response whether and, above all, how bowel
preparation and/or antibiotic therapy resulted in a modified rate of the anastomosis
leakage is still lacking and level 1 evidence are still missing[1,67]. Finally, independently
from dysbiosis, a causal inflammation role in the AL at the anastomotic site has been
advocated[68].  Involved innate immune response, mostly composed of neutrophils,
may exacerbate hypoxia in damaged tissues, consuming oxygen during oxidative
burst[69].  In emphasis, the use of non-steroidal anti-inflammatory drugs may seem
intriguing; however, they are not routinely indicated, essentially for their relation
with higher bleeding rate.
Other short-term outcomes
Ileus is any reduction of the normal propulsive activity of the bowel. After surgery, a
transient  impairment  of  the  peristalsis  always  happens  for  few  days.  For
postoperative ileus,  undeniable causal factors are the manipulation of the bowel
together with an excessive use of opioid drugs[3]. Nonetheless, experimental studies
with animal models revealed a potential role of the interplay microbiota-immune
system in postoperative ileus[70].  A potential  pathogenetic  mechanism involves a
peristaltic dysfunction, caused by intestinal nervous system response to intestinal
macrophages activated by the microbiota[71]. A recent study reported a reduction of
postoperative ileus rate after administration of oral non-absorbable antibiotics[66].
Similarly, preoperative oral intake of probiotics (Lactobacillus  and Bifidobacterium)
seems to enhance the return to the normal bowel function[51].  However,  a deeper
understanding of this relation is required to draft further studies[1].
In  prolonged  postoperative  ileus,  high  levels  of  IL-6  and  leucocyte  bowel
infiltration have been found, suggesting also a direct role of inflammation. These data
are  coherent  with  the  reduced  duration  of  postoperative  ileus  after  minimally
invasive surgery[68]. Finally, in animal models, it was also reported a possible causal
GM role in the formation of postoperative adhesions[70].
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Long-term outcomes: Intestinal microbiota and immunity as prognostic factors
Recurrence rate after curative CRC surgery is reported to be up to 40% and the great
majority of recurrence appears within 3 years from operation[6,72]. Local recurrence,
mostly perianastomotic in the extraluminal space, shows a reported rate ranging
between  1%  and  23%[21,73].  A  higher  incidence  of  local  recurrence  rate  has  been
observed after anastomotic leak. We can hypothesize different explanations: (1) A
delayed start  of  adjuvant  therapy;  (2)  Implant  of  exfoliated tumor cells  that  are
invariably persistent in the colon after resection[21]; and (3) A process of metachronous
initiation of a new tumor and new tumor promotion by a persistent inflammatory
status[74]. The last two possible mechanisms, together with the consequent reduction of
oral intakes, longer hospital stay (with major probabilities of nosocomial infections)
and aggravated surgical stress, have a strong relation with the GM alterations[21]. As
previously  stated,  anastomotic  leak  is  related  with  the  presence  of  microbes
producing MMPs[1,62].  Nevertheless, preoperative high serum level of MMP-2 and
MMP-9  has  been  reported  to  be  an  independent  marker  of  a  worse  oncological
outcome[75]. Increased proteolysis is also typical of more invasive tumors and it is not
only related with anastomotic leak[75]. Moreover, MMP-9 presence in tumor sample
was found in the 85% of patients with high serum level of MMP-9[75].
F. nucleatum and enterotoxigenic B. fragilis seem related with more advanced CRC
stages,  lower  rate  of  disease-free  survival  and,  consequently,  they  appear  to  be
responsible for a worse prognosis[33,76,77].
Kosumi  and  colleagues  evaluated  the  potential  prognostic  influence  of
Bifidobacterium  in  a  wide  cohort  of  1313  patients  affected  by  CRC[78].  The
Bifidobacterium presence in tumoral tissue was found in 30% of this cohort. Although
previously  published data  suggested a  protective  role  of  this  microorganism in
CRC[47-49], no significant association was found between Bifidobacterium number and
survival  rate.  Multiple  hypotheses  may  explain  this  finding:  (1)  Bifidobacteria
produce lactic acid that, in high level, may boost tumor growth reducing immune
response activation; (2) Bifidobacteria can also produce acetate that is utilized by
tumor tissue; and (3) Bifidobacteria may have different roles in healthy and tumoral
tissue  in  which  these  microbes  may  act  together  with  other  species  (e.g.,
Fusobacterium).  Nonetheless,  the number of  these microorganisms in CRC tissue
resulted associated with the extent of signet ring cells[78].
Expression levels of different cytokines seems also related to tumor prognosis[17].
High  IL-17  levels  predict  an  adverse  prognosis  with  a  rapid  development  of
metastasis[79]. Similarly, high level of let-7a microRNA family are related with lower
presence of CD3+ and CD45RO+ which significantly correlated with higher cancer-
related mortality[80].  On the contrary, high density of CD45RO+ cells within tumor
tissue has been proposed as an independent positive prognostic biomarker and it is
related with longer survival also independently from MSI status[81]. According to these
findings, traditional prognostic systems including the TNM classification system of
the American Joint Committee on Cancer and Union International Cancer Control
appear to be no longer sufficient to estimate patients’ oncological outcomes[82]. From
the joint effort of 14 centres with a proven expertise located in 13 countries of North
America, Europe and Asia, a consensus Immunoscore was created. It resulted from
the assessment by digital pathology of the density of specific T-cells (CD3+ and CD8+)
in the tumor sample and in the infiltrating margins. In order to assess the prognostic
role of the inflammatory infiltrate in tumoral tissue from primary resected CRC, the
resulting score was tested and validated in a study including 2681 patients[82]. Inter-
observer reproducibility of this score resulted high. Immunoscore revealed to be so
powerful in the prognostic stratification of the patients (in terms of time to recurrence,
disease-free  and  overall  survival  rates)  to  result  more  reliable  than  the  TNM
classification system suggesting the  necessity  to  create  a  unique and integrated
classification system[82]. Moreover, it seems also a survival predictor stronger than the
MSI status[83].  Overall,  the highest was the Immunoscore,  the lowest resulted the
recurrence rate at 3 years from surgery ranging from 5% in patients having high
Immunoscore to 26% in patients having low Immunoscore. Five-years overall survival
rates  were  82%,  77%  and  62%  in  high,  intermediate  and  low  Immunoscore,
respectively. Similar results were confirmed even after adjustment for the principals
known potential prognostic factors (e.g.,  demographic characteristics, TNM stage,
MicroSatellite Instability status). Ultimately, this score may represent a valuable tool
for tailored adjuvant chemotherapy[82].
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GUT MICROBIOTA-IMMUNITY INTERPLAY IN PATIENTS
UNDERGOING CHEMOTHERAPY AFTER CRC SURGERY
CRC is mostly treated with cytotoxic drugs including 5-fluorouracil, capecitabine
and/or platinum-based agents[21]. However, different chemotherapy regimens exist
and are actually administered according to tumor stage, patient’s general conditions
and mutational status. Details that are more specific will not be object of this review.
Microbiota may interfere with chemotherapy through different ways: Modification
of the GM composition, metabolisms of xenobiotics and modulation of the immune
response[84,85]. Consequently, the so-called “pharmacomicrobiomics” is increasingly
attracting  attention[85].  Unequivocally,  these  treatments  alter  the  composition  of
intestinal microbiota. In the previously cited paper of Deng et al[5], the demonstrated
reduction of Bacteroides (mostly B. ovatus) in surgically treated patients is higher when
compared with the reduction of this microorganism in the patients treated only with
chemotherapy. Therefore, surgery seems more effective than chemotherapy against
this potential pathogen[5].  Nevertheless,  other species such as Veillonella dispar  or
higher  abundance  of  Prevotella  copri  and Bacteroides  plebeius  were  found in  only
chemotherapy-treated patients[5].  However,  a relation between these quantitative
differences and the potential clinical impact has to be further analyzed.
Intestinal  microbiota  is  responsible  for  xenobiotic  metabolism.  According  to
experimental  results,  a  different  clinical  response  to  the  treatments  with
fluoropyrimidines seems related also with GM modifications other than with genetic
polymorphisms[86]. Previous papers have already emphasized the possible relation
between intestinal microbiota and chemoresistance in CRC patients[5]. F. nucleatum has
a causal role in chemoresistance via  the activation of the autophagy pathway. In
particular,  autophagosome  formation  is  activated  in  the  CRC  cells  with  the
production  of  their  related  proteins[87].  Consequently,  the  detection  of  copious
presence of this species may represent a prognostic biomarker for chemoresistance,
suggesting a probable modification in the administered chemotherapy[87]. High levels
of circulating IL-22 have also been described as associated with chemo-resistance[88].
Nevertheless,  high  levels  of  regulatory  T  cells  create  an  immunosuppressive
environment reducing the efficacy of the host antitumor immune system and of the
antiblastic therapy[89].
Chemotherapy treatments often cause chemotoxicity and the symptoms are mostly
diarrhea,  nausea,  mucositis  and  hand-foot  syndrome.  Dysbiosis  caused  by
chemotherapy administration has a causal role in colitis and diarrhea[85]. Anaerobic
species are usually reduced together with an inferior production of butyrate. Butyrate
is  a  short-chain fatty  acid (SCFA) responsible  for  the  trophysm of  the  intestinal
mucosa.  Nevertheless,  this  SCFA  has  an  antitumoral  action  blocking  cellular
replication, promoting apoptosis[85], stimulating the IL-10 production and inhibiting
the NF-κB activation[11]. Butyrate is also implicated in mucosal barrier efficacy through
higher production of mucus[11].
Finally, the microbiota appears also to have a direct causal role in chemotoxicity.
For example, irinotecan-induced mucositis is the consequence of the reactivation of its
liver metabolite from intestinal  bacterial  β-glucuronidases[85,90].  There are several
isoforms of β-glucuronidases, related to different toxicity levels[90]. On the contrary,
the  preservation  of  commensal  microbiota,  able  to  modulate  tumoral  micro-
environment, has been reported to be pivotal in an optimal response to chemotherapy
with oxaliplatin[91]. Nevertheless, a favorable gut microbiota may also have a role in
the reduction of these side effects[9].
The identification of  specific  microbes as predictor  of  chemotherapy response
together with a complete understanding of the mechanisms causing chemotoxicity
may allow a tailored therapy with the reduction of side effects[92].
FUTURES PERSPECTIVES: INNOVATIVE STRATEGIES FOR
CRC PREVENTION AND TREATMENT
Gut microbiota have a causal role in all the CRC steps, from its initiation to response
to chemotherapy.  Therefore,  new approaches microbiota-based may add further
possibilities  against  this  tumor.  Nevertheless,  high  expertise  in  “bacterial
management” is required.
Role of diet in cancer prevention
Since an inappropriate diet represents a major risk factor for CRC initiation, a diet rich
in fibers and vegetables, especially from cruciferous family, may aid in maintaining a
healthy microbiota. Nevertheless, specific supplementary nutrients may help from the
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cancer prevention to the avoidance of anastomotic leak after surgery[1,21]. Probiotic and
prebiotic  consumption  may  positively  modulate  metabolic  activity  of  the  gut
microbiota  with  a  lower  production  of  carcinogenic  compounds[41].  Moreover,
according to the results of in vitro studies, some microbes are able to bind genotoxic
compounds to their cellular wall[93].
SCFAs  are  the  results  of  bacterial  fermentation  of  complex  carbohydrates.
Conjugated linoleic acid has a suppressive action over cellular proliferation and
favors cellular apoptosis in a dose-dependent proportion[11]. It is produced by several
species including Lactobacillus casei and L. acidophilus[94]. Dietary supplementation with
nutrients able to increase the production of butyrate or other SCFAs may help in
maintaining a healthy and balanced microbiota[1]. Lactobacillus, Bifidobacterium and
Faecalibacterium prausnitzii may be used as probiotic with the same purposes together
with the maintenance of an active immunosurveillance[11,95]. It has also been reported
that  some  probiotics  may  change  the  equilibrium  between  Th1  and  Th2  cells
stimulating production of anti-inflammatory cytokines and suppressing the release of
pro-inflammatory cytokines [11].
Surely,  a  positive regulation of  the gut  microbiota and its  metabolic  activities
through the diet appears to be very interesting but certainly a challenging approach[2].
Since diet is only one of the multiple recognized risk factors for CRC, specific large-
scale and life-long studies on humans are extremely difficult even to draft other than
to interpret, indeed. Similarly, since some microbes have been reported to have both a
protective and harmful role, an excessive introduction of supplement with probiotics
may have additional negative effects and the limit in a population will  probably
remain unknown.
New diagnostic biomarkers
Colonoscopy is a very important examination in the CRC management, allowing to
locate the tumor into the colon and to obtain a preoperative histological diagnosis of
malignancies.  However,  patient’s  discomfort  more  than  the  possibility  of
complications may induce several patients to postpone the exam, leading to a late
diagnosis. Consequently, the research of new, less invasive diagnostic biomarkers
seems very important. High serum levels of MMP-2 and MMP-9 have been proposed
as biomarker for CCR and they seem to relate with particular cancer aggressiveness.
In a small sample study including 32 CRC patients and 11 controls (benign disease),
MMP-2 and MMP-9 resulted more reliable than traditional serum markers such as
CEA[75].  Analysis  of  microbes  from saliva samples  has  been suggested as  a  non-
invasive  new biomarker  of  CRC assuming  the  existence  of  a  correlation  in  GM
composition between mouth and gut[96]. However, our pilot study failed in finding a
significative difference of microbial saliva composition, comparing healthy controls
with patients affected by CRC[27].
As previously stated, microbial composition varies together with the progression
healthy-adenoma-adenocarcinoma[35-37,53]. On healthy volunteers, a great majority of
the  phylum  Firmicutes  has  been  found[27]  and  the  genera  Clostridium,  family
Lachnospiraceae, may represent a biomarker in stool sample for healthy people[5]. On
the contrary, the identification in stool samples of higher presence of Fusobacterium
nucleatum  in  CRC patients  when compared with healthy volunteers  suggests  its
possible role as a novel diagnostic biomarker[5,97]. Zackular et al[37] conducted a study to
demonstrate the potential as a screening tool of fecal modified microbiota. Data from
90 people (30 healthy, 30 with adenomas, 30 with adenocarcinomas) were analyzed.
The authors confirmed that the fecal microbial panel was more important than a
single  microbe  suggesting  CRC  as  polymicrobial  disease  and  they  found  a
significative difference between healthy and adenoma group.
However, further large-scale, case-control studies of multidisciplinary teams are
still required to confirm these findings and to obtain more information about bacterial
species at strain level. Nevertheless, the eventual correlation between microbiota and
other  not  modifiable  characteristics  of  the  patients  (e.g.,  sex  or  age)  should  be
evaluated, as well.
Perioperative management
In  perioperative  settings,  enhanced  recovery  after  surgery  programs  should  be
encouraged. A prolonged fasting of 6-12 h may profoundly alter GM composition and
it  seems  no  more  justifiable.  On  the  contrary,  supplementary  food  containing
microbes able to ferment acid lactic may allow an enhanced healing of the surgical
wound[1]. Nonetheless, in animal models, oral supplementation with non-absorbable
phosphate usually lacking after surgery, reduced bacterial related anastomotic leak[98].
Antibiotic therapy should be carefully administered and, when required, for the
shortest  needed period.  Opioid  drugs  should be  avoided and other  methods  of
analgesia  encouraged.  Bowel  preparation  should be  modified  in  order  to  try  to
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eliminate only, or mostly, virulent agents maintaining a helpful biodiversity[67].
The discovery of unevenness of species (i.e.,  V. dispar) in chemotherapy-treated
patients  still  misses  a  clinical  correlation[5].  Hopefully,  the recognition of  a  such
potential  biomarker  may  represent  a  supplementary  target  in  chemotherapy
modulation. Unraveling at least a part of the mechanisms of chemoresistance may
provide new strategies for chemotherapy optimization[5]. Similarly, the discovery of
favorable or unfavorable microbiota for chemoresistance and side effects may help in
tailoring chemotherapeutic regimens[85,92]. Immune system has both protective and
potential harmful role so the research of strategies to enhance positive action together
with the reduction of negative effects should be encouraged. Nevertheless, a deeper
understanding of immune-related cancer progression may provide new target for
immunotherapy in CRC[17,80].
CONCLUSION
In  conclusion,  microbiota-based  approaches  may  have  a  huge  impact  on  CRC
initiation, progression and treatments. However, most of the previously published
studies are performed on animal models or in small groups of humans. Moreover,
most of them are only “quantitative” and a correlation with the clinical impact of the
findings is still lacking. Finally, and above all, CRC and its “history” is multifactorial
so the evaluation of the impact of modification in gut microbiota composition on CRC
management is challenging but very intriguing.
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